LADW

LADW is a competitive inhibitor of purified ACE1, which binds to the active site of the enzyme or its adjacent region to block substrate binding. It potently inhibits purified ACE1 with an IC₅₀ of 28 μM, exhibiting a concentration-dependent inhibitory effect^[1].
LADW (150-300 μM; 24 h) promotes NO release and inhibits ET-1 secretion in EA.hy926 vascular endothelial cells in a concentration-dependent manner^[1].
LADW forms strong interactions with eNOS, ECE-1 and Furin via hydrogen bonds and van der Waals forces and binds to the key active residues of these proteins according to molecular docking results^[1].
LADW (15 min pre-incubation followed by 15 min reaction) potently inhibits α-glucosidase derived from Saccharomyces cerevisiae, with an IC₅₀ value of 4.40 mM, and its inhibitory activity is stronger than that of EEAEGT^[2].
LADW inhibits the hydrolysis of soluble starch during simulated gastrointestinal digestion by altering starch structure, reducing the production of reducing sugars by 39.56%^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.